Open Interest and Volume Dynamics
The latest data reveals that Mankind Pharma’s open interest (OI) in derivatives jumped by 8,216 contracts, a robust 38.99% increase from the previous tally of 21,071 to 29,287. This sharp rise in OI is accompanied by a substantial volume of 103,583 contracts traded, underscoring active positioning by market participants. The futures segment alone accounted for a value of approximately ₹17,925 lakhs, while options contributed a staggering ₹61,599.7 crores in notional value, culminating in a total derivatives value of ₹24,817 lakhs.
The underlying stock price closed at ₹2,443, having opened with a gap-up of 6.2% and touched an intraday high of ₹2,444.9, marking a 6.27% rise on the day. This price action, coupled with the surge in OI and volume, suggests that traders are increasingly bullish on Mankind Pharma’s near-term prospects.
Market Positioning and Directional Bets
The pronounced increase in open interest alongside rising volumes typically indicates fresh capital entering the market rather than mere position squaring. In Mankind Pharma’s case, the 38.99% OI growth, combined with a three-day consecutive gain delivering an 8.86% return, points to strong directional bets favouring upside momentum. The stock’s outperformance relative to its sector by 5.01% and the Sensex by 5.9% on the same day further corroborates this bullish sentiment.
Moreover, the stock is trading above all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – signalling a sustained uptrend. Rising delivery volumes, which increased by 23.62% to 3.72 lakh shares on 18 September compared to the five-day average, indicate growing investor conviction and participation in the underlying equity.
Liquidity and Tradeability
Mankind Pharma’s liquidity profile remains robust, with the stock’s traded value comfortably supporting trade sizes up to ₹2.51 crore based on 2% of the five-day average traded value. This liquidity ensures that institutional and retail investors can execute sizeable trades without significant market impact, facilitating smoother price discovery amid the current surge in derivatives activity.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
Mojo Score and Analyst Ratings
Mankind Pharma currently holds a Mojo Score of 50.0 with a Mojo Grade of Hold, reflecting a cautious stance despite recent bullish price action. This represents a downgrade from a previous Buy rating assigned on 3 August 2026. The mid-cap pharmaceutical company, with a market capitalisation of ₹98,536 crore, is navigating a complex environment where valuation concerns and sector headwinds temper enthusiasm.
Nonetheless, the stock’s recent outperformance and strong derivatives market activity suggest that traders are positioning for a potential re-rating or positive catalysts in the near term. The divergence between the Mojo Grade and market behaviour highlights the importance of monitoring evolving fundamentals and technical signals closely.
Sector and Benchmark Comparison
On 21 September 2026, Mankind Pharma’s one-day return stood at 6.19%, significantly outperforming the Pharmaceuticals & Biotechnology sector’s 1.18% gain and the Sensex’s modest 0.29% rise. This relative strength underscores the stock’s appeal amid broader market volatility and sector rotation.
The pharmaceutical sector continues to attract investor interest due to its defensive qualities and growth potential driven by innovation and expanding healthcare demand. Mankind Pharma’s active derivatives positioning and price momentum position it favourably within this context, although investors should remain mindful of valuation and regulatory risks.
Implications for Investors
The surge in open interest and volume in Mankind Pharma’s derivatives signals increased market conviction and potential for further price appreciation. Investors should consider this alongside the stock’s technical strength, rising delivery volumes, and liquidity profile when evaluating entry or exit points.
However, the Hold rating from MarketsMOJO suggests a balanced approach, recognising both the upside potential and the risks inherent in mid-cap pharmaceutical stocks. Close monitoring of quarterly earnings, sector developments, and broader market trends will be essential to capitalise on emerging opportunities while managing downside risks.
Mankind Pharma Ltd or something better? Our SwitchER feature analyzes this mid-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Conclusion
The recent surge in open interest and trading volumes in Mankind Pharma’s derivatives market reflects a growing bullish sentiment and active repositioning by investors. Supported by strong price gains, rising delivery volumes, and favourable technical indicators, the stock is attracting renewed attention within the mid-cap pharmaceutical space.
While the current Mojo Grade of Hold advises caution, the evolving market dynamics and sector tailwinds suggest that Mankind Pharma remains a key stock to watch. Investors should weigh the positive momentum against valuation and sector risks, using a disciplined approach to capitalise on potential upside while safeguarding capital.
Overall, the derivatives market activity provides valuable insight into market expectations and positioning, signalling that Mankind Pharma could be poised for further gains if favourable catalysts materialise.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
